DR-10627 is under clinical development by Zhejiang Doer Biologics and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DR-10627’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DR-10627 overview
DR-10627 is under development for the treatment of diabetes and obesity, non-alcoholic steatohepatitis (NASH) and unspecified metabolic disorders. The drug candidate is a bi-specific fusion protein targeting gastric inhibitory polypeptide receptor (GIPR) and glucagon like peptide 1 receptor (GLP1R). It is developed based on MultiBody platform technology.
Zhejiang Doer Biologics overview
Zhejiang Doer Biologics, is a company involved in the development of innovative multi-specific protein drugs. The company is headquartered in China.
For a complete picture of DR-10627’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
